These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 20668437)

  • 41. Altered Brain Entropy as a predictor of antidepressant response in major depressive disorder.
    Liu X; Song D; Yin Y; Xie C; Zhang H; Zhang H; Zhang Z; Wang Z; Yuan Y
    J Affect Disord; 2020 Jan; 260():716-721. PubMed ID: 31563070
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pregenual or subgenual anterior cingulate cortex as potential effective region for brain stimulation of depression.
    Jing Y; Zhao N; Deng XP; Feng ZJ; Huang GF; Meng M; Zang YF; Wang J
    Brain Behav; 2020 Apr; 10(4):e01591. PubMed ID: 32147973
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.
    Detke MJ; Lu Y; Goldstein DJ; McNamara RK; Demitrack MA
    J Psychiatr Res; 2002; 36(6):383-90. PubMed ID: 12393307
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Duloxetine for the treatment of major depressive disorder.
    Nemeroff CB; Schatzberg AF; Goldstein DJ; Detke MJ; Mallinckrodt C; Lu Y; Tran PV
    Psychopharmacol Bull; 2002; 36(4):106-32. PubMed ID: 12858150
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Duloxetine for childhood depression with pain and dissociative symptoms.
    Desarkar P; Das A; Sinha VK
    Eur Child Adolesc Psychiatry; 2006 Dec; 15(8):496-9. PubMed ID: 16732464
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression.
    Shelton RC; Andorn AC; Mallinckrodt CH; Wohlreich MM; Raskin J; Watkin JG; Detke MJ
    Int Clin Psychopharmacol; 2007 Nov; 22(6):348-55. PubMed ID: 17917553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder.
    Raskin J; Xu JY; Kajdasz DK
    Int Psychogeriatr; 2008 Apr; 20(2):309-27. PubMed ID: 17588276
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
    Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
    Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.
    Arnold LM; Rosen A; Pritchett YL; D'Souza DN; Goldstein DJ; Iyengar S; Wernicke JF
    Pain; 2005 Dec; 119(1-3):5-15. PubMed ID: 16298061
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder.
    Ye W; Zhao Y; Robinson RL; Swindle RW
    BMC Psychiatry; 2011 Jan; 11():19. PubMed ID: 21281479
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of the antidepressant medication duloxetine on brain metabolites in persistent depressive disorder: A randomized, controlled trial.
    Bansal R; Hellerstein DJ; Sawardekar S; O'Neill J; Peterson BS
    PLoS One; 2019; 14(7):e0219679. PubMed ID: 31323045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
    Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
    BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder.
    Fishbain DA; Detke MJ; Wernicke J; Chappell AS; Kajdasz DK
    Curr Med Res Opin; 2008 Nov; 24(11):3105-15. PubMed ID: 18828958
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.
    Goldstein DJ; Lu Y; Detke MJ; Wiltse C; Mallinckrodt C; Demitrack MA
    J Clin Psychopharmacol; 2004 Aug; 24(4):389-99. PubMed ID: 15232330
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies.
    Mancini M; Sheehan DV; Demyttenaere K; Amore M; Deberdt W; Quail D; Sagman D
    Int Clin Psychopharmacol; 2012 Nov; 27(6):298-309. PubMed ID: 22954893
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder.
    Fava M; Wiltse C; Walker D; Brecht S; Chen A; Perahia D
    J Affect Disord; 2009 Mar; 113(3):263-71. PubMed ID: 18625521
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder.
    Sheehan DV; Meyers AL; Prakash A; Robinson MJ; Swindle RW; Russell JM; Mallinckrodt CH
    Curr Med Res Opin; 2008 Sep; 24(9):2457-66. PubMed ID: 18662492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds.
    Fornaro M; Rocchi G; Escelsior A; Contini P; Martino M
    J Affect Disord; 2013 Mar; 145(3):300-7. PubMed ID: 22981313
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
    Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
    Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.